298 related articles for article (PubMed ID: 22615564)
1. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
Jochum S; Moosmann A; Lang S; Hammerschmidt W; Zeidler R
PLoS Pathog; 2012; 8(5):e1002704. PubMed ID: 22615564
[TBL] [Abstract][Full Text] [Related]
2. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
[TBL] [Abstract][Full Text] [Related]
3. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas.
Xu ZG; Iwatsuki K; Oyama N; Ohtsuka M; Satoh M; Kikuchi S; Akiba H; Kaneko F
Br J Cancer; 2001 Apr; 84(7):920-5. PubMed ID: 11286472
[TBL] [Abstract][Full Text] [Related]
4. Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.
Strong MJ; Laskow T; Nakhoul H; Blanchard E; Liu Y; Wang X; Baddoo M; Lin Z; Yin Q; Flemington EK
J Virol; 2015 Oct; 89(19):10110-4. PubMed ID: 26178981
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
6. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
Quinn LL; Zuo J; Abbott RJ; Shannon-Lowe C; Tierney RJ; Hislop AD; Rowe M
PLoS Pathog; 2014 Aug; 10(8):e1004322. PubMed ID: 25144360
[TBL] [Abstract][Full Text] [Related]
7. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.
Horst D; van Leeuwen D; Croft NP; Garstka MA; Hislop AD; Kremmer E; Rickinson AB; Wiertz EJ; Ressing ME
J Immunol; 2009 Feb; 182(4):2313-24. PubMed ID: 19201886
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.
Horst D; Burrows SR; Gatherer D; van Wilgenburg B; Bell MJ; Boer IG; Ressing ME; Wiertz EJ
J Virol; 2012 Jan; 86(1):572-7. PubMed ID: 22013037
[TBL] [Abstract][Full Text] [Related]
9. EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.
Horst D; Favaloro V; Vilardi F; van Leeuwen HC; Garstka MA; Hislop AD; Rabu C; Kremmer E; Rickinson AB; High S; Dobberstein B; Ressing ME; Wiertz EJ
J Immunol; 2011 Mar; 186(6):3594-605. PubMed ID: 21296983
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of activation of the BNLF2a immune evasion gene of Epstein-Barr virus by Zta.
Almohammed R; Osborn K; Ramasubramanyan S; Perez-Fernandez IBN; Godfrey A; Mancini EJ; Sinclair AJ
J Gen Virol; 2018 Jun; 99(6):805-817. PubMed ID: 29580369
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr viral BNLF2a protein hijacks the tail-anchored protein insertion machinery to block antigen processing by the transport complex TAP.
Wycisk AI; Lin J; Loch S; Hobohm K; Funke J; Wieneke R; Koch J; Skach WR; Mayerhofer PU; Tampé R
J Biol Chem; 2011 Dec; 286(48):41402-41412. PubMed ID: 21984826
[TBL] [Abstract][Full Text] [Related]
13. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.
Ressing ME; Keating SE; van Leeuwen D; Koppers-Lalic D; Pappworth IY; Wiertz EJ; Rowe M
J Immunol; 2005 Jun; 174(11):6829-38. PubMed ID: 15905524
[TBL] [Abstract][Full Text] [Related]
14. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
[TBL] [Abstract][Full Text] [Related]
15. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
16. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
Adhikary D; Behrends U; Boerschmann H; Pfünder A; Burdach S; Moosmann A; Witter K; Bornkamm GW; Mautner J
PLoS One; 2007 Jul; 2(7):e583. PubMed ID: 17611619
[TBL] [Abstract][Full Text] [Related]
17. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.
Abbott RJ; Pachnio A; Pedroza-Pacheco I; Leese AM; Begum J; Long HM; Croom-Carter D; Stacey A; Moss PAH; Hislop AD; Borrow P; Rickinson AB; Bell AI
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835490
[TBL] [Abstract][Full Text] [Related]
18. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2.
Zuo J; Thomas WA; Haigh TA; Fitzsimmons L; Long HM; Hislop AD; Taylor GS; Rowe M
PLoS Pathog; 2011 Dec; 7(12):e1002455. PubMed ID: 22216005
[TBL] [Abstract][Full Text] [Related]
20. Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle.
Williams LR; Quinn LL; Rowe M; Zuo J
J Virol; 2016 Jan; 90(2):947-58. PubMed ID: 26537677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
